HomeORGANIZATION
ORGANIZATION

Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
(Oct.29.2018)

EFPIA Japan Pricing & Economics Committee Chairman Kuniyuki Hara (left), Access Committee Chair Yasuko Aitoku
If Japan is to roll out a full-scale cost-effective assessment (CEA) scheme, it should be positioned as a supplemental tool for drug pricing and its use be confined to drugs with a certain level of sales that have been granted pricing premiums at launch, EFPIA officials say ...
(LOG IN FOR FULL STORY)